
|Videos|February 7, 2015
PARP Inhibitors for Ovarian Cancer
Author(s)Donna McNamara, MD
Donna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.
Advertisement
Clinical Pearls
Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, discusses PARP inhibitors for the treatment of ovarian cancer.
- In breast cancer, maintenance drugs exist to keep patients in remission following chemotherapy. There remains a need for such agents in ovarian cancer.
- Though only 10-15% of patients harbor a BRCA1/2 mutation, they may see benefit from treatment with a PARP inhibitor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5


















